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INTRODUCTION 
Adnexal mass is a lump arising from structures closely related to 
uterus such as fallopian tube, ovaries and surrounding connective tissue. 
Adnexal mass can be benign or malignant .(1)  
Most of the adnexal mass lesions are seen arising from ovaries. 
Ovarian lesions can be benign lesions or malignant masses. Ovarian 
malignancy is one of the most common causes of death from gynecologic 
tumors. Ovarian neoplasm is very rarely detected in early stage and it is 
far advanced at the time of diagnosis. Detection of ovarian tumor at very 
advanced stages makes the treatment very difficult.(2)                              
Causes of adnexal mass lesion may be benign or malignant. Benign 
lesions are simple functional cyst, serous cystadenoma, mucinous 
cystadenoma, endometriotic cyst, fibroma, thecoma, Brenner tumour 
tuboovarian cyst or hydrosalphinx. Malignant lesions are serous 
cystadenoarcinoma, mucinous cystadenocarcinoma, endometrotic 
carcinoma immature teratoma, dysgerminoma, krukenbergs tumor. Cause 
of adnexal mass lesion varies with different age group.(3) 
Incidence of ovarian carcinoma is increasing in recent times. 
Ovarian ca is responsible for 3.6 % of all cancer cases, with a mortality of 
4.3%. It was estimated by “American Cancer Society” and “National 
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Cancer Institute” that 21,980 new cases of ovarian cancer will be 
diagnosed approximately every year and 14,270 women will die due to 
complications of the disease.(1) 
Ultrasonography (US), Computed Tomography (CT), and 
Magnetic Resonance Imaging (MRI)  can be  used to evaluate ovarian 
mass. The first imaging modality for characterization of adnexal mass 
lesion is Ultrasonogram. Investigation of choice for adnexal mass is MRI 
because it gives a better spatial and contrast resolution in delineation of 
anatomical structures as well as characterization of pathological 
lesions.(4) 
MRI well delineates the abnormalities in female reproductive 
organs disorders  including myomas, ovarian mass lesions, adenomyosis, 
cervical lesions , endometrial malignancy etc.(5) 
Treatment of ovarian carcinoma depends on the stage of the 
disease, age and severity of symptoms in the patients. Surgery is the 
primary modality of treatment however many patients require pre or post 
operative chemotherapy. Surgical treatment may range from optimal 
debulking surgery to total abdominal hysterectomy with bilateral 
salphingo oophrectomy. In medical unfit patients initially chemotherapy 
may be given followed by surgery later. Hormonal therapy is used in 
patients requiring break from chemotherapy due to intolerance and 
patients with recurrent lesions without symptoms.(6) 
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REVIEW OF LITERATURE 
ANATOMY OF ADNEXA 
Adnexa composed of  structures that are closely related structuraly 
and functionally to the uterus.(7) 
Adnexa is made up of Fallopian tube  Ovaries  Broad ligament.  
OVARY: (7) 
Each ovary is ovoid in shape and measures approximately  1.5 x 
3cm and weighs 2 – 8 grams . Ovaries composed of medulla and cortex. 
Cortex made up of ovarian follicles in different stages of 
development and is embedded in dense fibrocellullar stroma.                                 
Ovarian medulla  is highly vascular and receives vessels from 
ovarian hilum. Tunica albuginea covers the ovary. 
Ovarian fossa bounded superiorly by external iliac vessels and 
anteriorly by obliterated umbilical artery and behind by ureter.  
Long axis of ovary oriented in craniocaudal position. Suspensory 
ligament inserts at superior pole of ovary together with ovarian fimbriae 
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of fallopian tube. Inferior pole of ovary attatched to uterus by ovarian 
ligament. 
ARTERIAL SUPPLY:(7) 
Ovaries had dual blood supply, 
1. Ovarian artery originate laterally from aorta, below renal artery. 
2. Ovarian branches of  uterine artery run in broad ligament to supply 
ovaries 
VENOUS DRAINAGE: 
Right ovarian vein drains into inferior vena cava. Left ovarian vein 
drains into left renal vein. Ovarian veins form a plexus in broad ligament 
that communicate with uterine venous plexus. 
LYMPHATIC DRAINAGE: 
Lymphatic drainage into preaortic  and lateral aortic lymphnodes. 
NERVE SUPPLY 
Ovarian plexus is formed by branches from aortic, renal, superior 
hypogastric and inferior hypogastric plexuses. 
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FALLOPIAN TUBE:(7,8) 
Fallopian tube is 10-12 cm length. It bridges between ovaries 
laterally and uterus medially. Lateral end of fallopian tube is like funnel 
called infundibulum. It bears number of finger like process called 
fimbriae. One of the fimbriae is longer than others called ovarian 
fimbriae. Ampulla is dilated tortuous tube structure  and forms laterl two 
thirds of the tube. Isthmus is narrow cord like structure forms medial one 
third of the tube. Interstitial part of the tube lies within the wall of the 
uterus. 
ARTERIAL SUPPLY(7) 
Uterine artery supplies medial two third of the tube and ovarian 
artery supplies lateral one third if the tube. 
VENOUS DRAINAGE: 
Veins run parallel with arteries and drain into pampniform plexus 
of ovary and into uterine veins. 
UTERUS:(7,9) 
The uterus has two parts : body and cervix. The body is the upper 
expanded portion and forms upper two thirds whereas the cervix  is the 
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lower cylindrical portion which forms the lower one third of the organ. 
The constriction situated between the body and cervix is called the 
isthmus 
ARTERIAL SUPPLY: 
Uterus supplied by - Uterine artery a branch of anterior division of 
internal iliac artery and ovarian artery 
VENOUS DRAINAGE: 
Venous plexus drains into internal iliac veins. 
LYMPHATIC DRAINAGE: 
Lymphatic drainage into internal & external iliac node and sacral 
lymphnodes. 
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EMBRYOLOGY OF FEMALE GENITAL TRACT 
 
 
OVARIES: 
The number of ovarian follicles are  number limited, and about 
300,000 to 2,000,000 are present at birth. They contain a specific 
reproductive cell, the oocyte, at the primary stage, with 46 chromosomes 
Of the initial stock of primordial follicles, approximately 300 develop 
between puberty and menopause to produce fertilizable ova.(10) 
Develops from medial part of the genital ridge.  
Urogenital 
system 
develops 
from
mesoderm of 
the 
intermediate 
cell mass
Medial part
Atropies in 
female
Middle part
Gives rises 
to ovaries
Lateral part
Gives rise to 
fallopian tube , 
uterus and upper 
3/4th of vagina
urogenital 
sinus
(anterior part 
of cloaca)
Gives rise to 
lower 1/4th 
of vagina and 
vulva
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At 4 weeks gestation , primordial germ cells originate from yolk 
sac then migrate to genital ridge .(11) 
At 12 weeks formation of mesentry of ovary as a result of 
projection of  ovary into coelomic cavity.(11) 
The ovary descends in the abdominal cavity with 2 ligaments (12) 
Ist ligament - Suspensory ligament attatched to cephalic pole  - 
Infundibulopelvic ligament 
IInd ligament -  Gubernaculum which is attached the caudal end of 
ovary  and the abdominal parities at the inguinal region –  
Proximal part – Ovarian ligament 
Distal part – Round ligament 
FALLOPIAN TUBE:(11) 
Fallopian tube develop from upper parts of mullarain ducts 
UTERUS:(11) 
Uterus develops from middle part of mullerian ducts  after their 
fusion and  canalization. 
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RISK FACTORS 
Lifetime risk estimate is two to five times for individuals who have 
one first degree relative with ovarian cancer (13).  
Long-term users of hormone replacement therapy slightly increase 
ovarian cancer risk (14).  
Up to age 60 years of age ,  30% lifetime risk of ovarian cancer  is 
conferred due to mutations in the BRCA1 gene (13). 
Up to age 70 years of age ,  27% lifetime risk of ovarian cancer  is 
conferred due to mutations in the BRCA2 gene(15).   
High-grade serous carcinomas show  p53 is mutations in 50% or 
more cases(16).  
Half of low-grade serous carcinomas shows activating mutation 
of  KRAS or BRAF are present (17). 
 Ovarian serous carcinomas is seen to be associated with mutation 
of other tumor suppressor genes and oncogenes such as BRCA1/2, PTEN, 
and PIK3CA (18) .  
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Ovarian serous carcinomas  exhibits amplification/copy number 
gains in HER2/neu (ERBB2)(14). 75% of ovarian mucinous carcinomas  
shows KRAS mutation. (19) 
Increased risk of ovarian cancer as well as breast cancer is seen in 
women  who have history of early menstruation / late menopause(20). 
80% of malignant ovarian mass patient show increased levels of  
serum CA-125 levels (>35 U/mL) at radioimmunoassay.  CA-125 is not a 
tumor-specific antigen. CA 125  is also elevated in approximately 1% of 
healthy control subjects, in patients with liver cirrhosis, endometriosis 
and pelvic inflammatory disease.(21) 
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IMAGING IN ADNEXAL LESIONS 
ULTRASONOGRAM: 
Till date Ultrasonography is the primary imaging modality of 
choice for pelvic mass evaluation because of its easy availability , cost 
effectiveness , high sensitivity and absence of ionizing radiation.(22) 
COLOR DOPPLER: 
Resistive index identified using color Doppler can be used to 
differentiate benign and malignant neoplasms. Resistive index less than 
0.4 is considered suspicious of malignancy(22).  
Lack of uniqueness and overlap of findings limits the utility of 
Color Doppler as a primary modality of investigations for neoplasms(22). 
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COMPUTED TOMOGRAPHY(23) 
Computed tomography has advantages of obtaining thinner 
sections and better spatial resolution. Because of faster imaging , CT is 
used for  characterization of adnexal mass and staging work-up of ovarian 
malignancy. Computed Tomography has 79% sensitivity and 75% 
specificity indicating suboptimal  prediction of cytoreduction.(23) 
MAGNETIC RESONANCE IMAGING: 
In most cases Contrast Enhanced Magnetic Resonance Imaging is 
of great help in differentiating benign and malignant ovarian mass due to 
better characterization of tissues and excellent delineation of anatomical  
structures [24].  
              Study by Reles et al showed that the sensitivity of Colour 
Doppler US in premenopausal patients was 80% and specificity only 
67%, whereas the sensitivity and specificity were 93% and 83%, in 
postmenopausal patients respectively (25) . 
MR imaging  is superior to Doppler US in characterization of 
malignant ovarian disease (26). 
Guerra et al MRI has a higher accuracy of 95% in differentiating 
between malignant and non-malignant adnexal lesions (27) . 
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Valentini et al. substantiated the findings of Saini et all about MRI 
imaging features of malignant adnexal neoplasm. He added that 
”heterogeneous and early enhancement pattern of lesion” is also 
suggestive of malignancy.(28)) 
MRI serves as a sensitive and specific investigation compared  to 
Doppler ultrasound and contrast enhanced CT in characterization of  
masses (26). Sonographically indeterminate ovarian mass lesions 
evaluated with MRI had a  sensitivity and specificity of 100% and 94%, 
respectively (29) . 
Borderline ovarian tumors showing early enhancement is  a better 
predictor of malignancy than CA-125 levels and sonographic findings 
(30). 
The following criteria is used for diagnosis of malignant adnexal 
lesions with MR imaging (31). 
Mass size larger than 4 cm 
Predominantly solid lesions 
Presence of necrosis on contrast-enhanced solid lesions 
Contrast-enhanced papillary projections  
Septal thickness 3 mm in cystic lesions 
Bilaterality 
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Younger age groups are more prone to develop benign epithelial 
tumors and these lesions are predominantly cystic in appearance.(32) 
Malignant epithelial tumours have major solid components and few 
cysic structure. The two most common subtypes of epithelial neoplasms 
are serous and mucinous tumors.(32) 
The striking characteristic feature of surface epithelial neoplastic 
tumor of the ovary is papillary projections.(33) 
Hypointense fibrous core with a hyperintense strome that is 
edematous demonstrated on T2 weighted MR image is a single best 
predictor of epithelial ovarian tumor. This feature correlates with the 
aggressive nature of the tumor.(33)  
Benign epithelial tumors:(34) 
Diameter less than 4 cm,  
Entirely cystic components  
Wall thickness less than 3 mm  
Lack of internal structure 
Absence of both ascites  
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CLASSIFICATION OF OVARIAN TUMOR(35) 
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WHO CLASSIFICATION OF OVARIAN TUMORS (35) 
SURFACE EPITHELIAL - STROMAL TUMORS 
Serous tumors: 
Benign (cystadenoma) 
Borderline tumors (serous borderline tumor) 
Malignant (serous adenocarcinoma) 
Mucinous tumors, endocervical-like and intestinal type: 
Benign (cystadenoma) 
Borderline tumors (mucinous borderline tumor) 
Malignant (mucinous adenocarcinoma) 
Endometrioid tumors: 
Benign (cystadenoma) 
Borderline tumors (endometrioid borderline tumor) 
Malignant (endometrioid adenocarcinoma) 
Clear cell tumors: 
Benign 
Borderline tumors 
Malignant (clear cell adenocarcinoma) 
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Transitional cell tumors: 
Brenner tumor 
Brenner tumor of borderline malignancy 
Malignant Brenner tumor 
Transitional cell carcinoma (non-Brenner type) 
Epithelial-stromal: 
Adenosarcoma 
Carcinosarcoma (formerly mixed Mullerian tumors) 
SEX CORD - STROMAL TUMORS 
Granulosa tumors: 
Fibromas 
Fibrothecomas 
Thecomas 
Sertoli cell tumors: 
Leydig cell tumors 
Sex cord tumor with annular tubules 
Gynandroblastoma 
Steroid (lipid) cell tumors 
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GERM CELL TUMORS 
Teratoma: 
Immature 
Mature 
Solid 
Cystic (dermoid cyst) 
Monodermal (e.g., struma ovarii, carcinoid) 
Dysgerminoma 
Yolk sac tumor (endodermal sinus tumor) 
Mixed germ cell tumors 
MALIGNANT, NOT OTHERWISE SPECIFIED 
Metastatic cancer from nonovarian primary: 
Colonic, appendiceal 
Gastric 
Breast 
STEPS IN DISSEMINATION 
Ovarian cancer will affect the body in three different stages:(35,23) 
ATTACK: Malignant ovarian tumor grows rapidly and attacks the 
healthy organs adjacent to it like  uterus and fallopian tubes. 
 
 
30 
EXPAND: Malignant cells are prone to break from the main tumor 
and there is high likelihood of seeding of malignant cells in abdomen and 
there by forming new tumors. 
SPREAD: The propensity of spreading to the anatomical 
landmarks like  chest , pelvis and abdomen increases when the malignant 
cells gets broken away and enters the lymphatic system. Haematogenous 
entry may cause dissemination to liver and lungs. 
Some researches call ovarian tumor as “silent killer” because of the 
lack of perceptible symptoms until the late stages of the disease. 
Nature of serous ovarian neoplasms:(36) 
Type of serous ovarian neoplasm Percentage 
Low malignant potential 15% 
Benign cystadenoma 60% 
Malignant cystadenoma 25% 
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Nature of mucinous ovarian neoplasms:(36) 
Type of mucinous ovarian neoplasm Percentage 
Low malignant potential 10 to 15% 
Smooth walled Benign cystadenoma 80% 
Highly malignant potential 5 - 10% 
 
Serous cystadenoma: 
Serous cystadenoma is unilocular most of the times with a thin wall 
measuring less than 3mm . (37) 
T1 and T2 weighted images of serous cystadenoma shows low 
signal intensity and homogenous high signal intensity respectively. These 
lesions does not show significant post contrast enhancement.(37) 
They are smaller than mucinous cystadenoma. Bilaterality is a 
common finding in serous cystadenoma.(37) 
Mucinous cystadenoma: 
Mucinous cystadenoma appears larger in size compared to serous 
cystadenoma.(37) 
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Mucinous cystadenoma gives honeycomb like appearance due to 
multiple locules (multilocular) with multiple thin regular  septations and 
wall which lacks endo or exocytic  vegetation on Ultrasonogram or MRI.  
These does not show significant enhancement after contrast 
administration.(37) 
Granulosa cell tumours  
Mostly benign   
Manifest by producing hormones with hyperestrogenism.  
There are two main subtypes of Granulosa cell tumours namely 
adult and juvenile types. (37) 
Hyperestrogenism results in  endometrial hyperplasia , atypical 
bleeding and  pseudoprecocity.(37)  
Granulosa cell tumours mostly appears as both cystic and solid 
masses, but it can be multilocular cystic or a predominantly solid 
lesions.(37) 
Yolk sac tumour / endodermal sinus tumour: 
Constitutes 1 % of ovarian tumors.  
Presents in the second or third decade  
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Appears as a large mixed lesions with both cystic and solid 
component  
Bright dot sign due to foci of enhancement due to dilated vessels 
due to increased vascularity.(38) 
Brenner tumour / transitional cell tumour 
Represents 2 % of ovarian neoplasms.  
Mostly benign. 
Due to solid fibrous component Brenner tumor shows low signal 
intensity on T2-weighted image.  
Very rarely areas of calcification can be present within the solid 
components of Brenner tumour and hence MRI demonstrates a lesion 
with both cystic and solid components .(39) 
Dysgerminoma: 
Dysgerminoma is seen as lobulated solid lesion with fibrovascular 
septa and a surrounding fibrotic capsule.  
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On T2-weighted images  solid component shows intermediate to 
high signal intensity, whereas the septa shows low signal intensity, but 
there is significant enhancement on contrast administration.(38) 
Sex cord stromal tumours: 
           Sex cord-stromal tumours includes fibromas,thecomas and 
fibrothecomas These are the most common benign solid lesion of the 
ovaries.(39) 
Fibrothecomas consist of both fibrous tissue and lipid containing 
theca cells. Usually seen as a well-circumscribed mass with 
predominantly solid component showing  T1-weighted  low to 
intermediate signal intensity and T2-weighted low signal intensity. (40)  
 
  
Meigs 
syndrome
Ovarian 
fibroma
Ascites
Pleural 
effusion
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Sertoli-Leydig cell tumours: (38,41) 
0.5 % of ovarian tumours  
Responsible for hyperandrogenism  
Most common virilizing tumours.  
Young women are mostly affected and they show signs of 
increased androgen activity.  
Sertoli-Leydig cell tumours are mostly solid lesions but they may 
also  present as lobulated heterogeneous lesions with both cystic and solid 
components.(41) 
These does not show significant enhancement after contrast 
administration.(38) 
Teratoma: 
Mature cystic teratoma constitutes tissues of all the three layers of 
embryogenic germ cells.Most commonly seen in women less than 
45years of age. (37) 
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Composed of hair follicle, sebaceous material, skin glands and 
muscles. Rokitansky nodule is a raised protuberance seen within the cyst 
containing hair, bone and teeth.(37) 
Endometroid carcinoma: 
10%-15% of ovarian carcinoma is Endometroid carcinomas.(42) 
They are the most common malignant neoplasm arising within 
endometriosis (42) 
Endometrioid tumors  are bilateral in 30%-50% patients. 
Endometrial hyperplasia is expected to have association with 
endometrioid carcinoma.(42) 
Clear cell carcinoma: (43) 
Represents  5% of ovarian malignancies. 
Mostly seen in patients having endometriosis. 
On imaging it appears as a unilocular cyst or large cyst protrusions 
which are solid in nature. 
Lesion demonstrates minimal post contrast enhancement.(43) 
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Ovarian metastasis (44) 
Constitutes 5 % of malignant ovarian tumours 
Most common primaries to metastasize to ovary are Stomach, 
colon, breast, lung and contralateral ovary. 
Modes of spread :   
direct invasion 
transcoelomic dissemination 
hematogeneous spread 
lymphatic spread 
Krukenberg tumours (44) 
Metastatic lesions to the ovary from a gastrointestinal cancer.  
The classical feature of Krukenberg tumor is the presence of 
mucin-producing signet-ring cells.  
Mostly  bilateral with a cystic and solid or a predominantly solid 
component.  
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Gadolinium administration shows enhancement of cyst wall and 
enhancement of  the solid component. 
Hydrosalphinx:(45) 
Fluid filled fallopian tube is called Hydrosalpinx.  
Distension of fallopian tube with pus / blood is called as 
pyosalphinx and haematosalphinx respectively.  
Pyosalpinx show high signal intensity on diffusion-weighted 
images and hematosalpinx exhibit high signal intensity on T1-weighted 
images. 
Features of functional cyst:(33) 
Thin walled (< 3 mm) 
Unilocular 
Presence of posterior acoustic enhancement(33) 
Endometriotic cysts / endometriomas / chocolate cysts: (46) 
bilateral 
cystic to complex adnexal masses with 
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high signal intensity on T1-weighted and  
intermediate to low signal intensity on T2-weighted images.  
“Shading sign” - Gradual loss of signal intensity  caused by 
repeated bleeding within the cyst in T2 weighted sequences.(46) 
Tubo- ovarian abscess:(47,48) 
Acute pyogenic infection of female genital tract  
Imaging features: 
        Thick walled fallopian tube 
Enlarged edematous ovaries with fluid distended fallopian tube and 
inflammatory changes in pelvic structures. 
Usg: 
Multilocular / unilocular complex thick walled cystic adnexal 
mass. 
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MRI: 
Ill defined adnexal mass with thick irregular walls containing fluid 
,which appears hypointense in T1 and hyperintense in T2 sequence. 
Post contrast MRI shows intense enhancement of the lesion. 
STAGING OF OVARIAN CARCINOMA (49) 
FIGO Staging of ovarian carcinoma 
Stage I: Tumour limited to ovaries 
Ia – Tumor limited to one ovary,capsule intact, no tumor on 
ovarian surface,no malignant cells in ascites or peritoneal washings   
Ib- – tumor limited to both ovaries, capsule intact, no tumor on 
ovarian surface,no malignant cells in ascites or peritoneal washings   
Ic- Tumor limited to one or both ovaries with any of the 
following:capsule rupture, tumor on ovarian surface , malignant cells in 
ascites or peritoneal washings   
Stage II: Tumor involves one or both ovaries with pelvic 
extensions or implants 
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IIa- tumor involves uterus or fallopian tubes,no malignant cells in 
ascites or peritoneal washings 
IIb- Tumor involves other pelvic tissues, no malignant cells in 
ascites or peritoneal washings 
Stage III: Tumor involves one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis 
IIIa – Microscopicaly confirmed peritoneal metastasis outside the 
pelvis  
IIIb – Macroscopicaly peritoneal metastasis outside the pelvis < 
2cm  
IIIc – Macroscopicaly peritoneal metastasis outside the pelvis 
>2cm  
Stage IV: Distant metastasis beyond the peritoneal cavity 
Enlarged lymphnodes above renal hilum 
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TREATMENT 
STAGE TREATMENT 
I Primary cytoreduction 
II Primary cytoreduction 
III 
Neoadjuvant chemotherapy and interval 
cytoreduction 
IV Neoadjuvant chemotherapy 
 
Treatment of ovarian cancer depends on the stage of the cancer that 
is a reflection of spread of the lesion to distant or adjacent site.  
Most commonly 2 forms of treatment of ovarian cancer is 
used.(50) 
1. Primary choice is surgery in which cancer is removed from the 
ovary and from as many other sites as possible. 
2. Chemotherapy 
The main objective of surgery is confirmation the diagnosis by 
sending the specimen for HPE, define the extension of disease, and 
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resection of  all visible tumor. The decision of appropriate surgical 
approach depends largely on the extension of lesion  and  requirement to 
retain the fertility. 
CYTOREDUCTIVE SURGERY(51) 
Reduction of as much tumor volume  as possible y surgical 
removal is known as cytoreduction or cytoreductive surgery. 
INTERVAL DEBULKING SURGERY(51) 
Interval debulking surgery is defined as a second operation 
performed after 3 or 4 cycles of platinum chemotherapy in woman who 
had suboptimal debulking primary surgery 
LAPAROSCOPIC SURGERY(52) 
Laparoscopic surgery is used for diagnostic purposes in low risk 
patients for ovarian cancer and removal of  cystic masses in patients who 
meets the following criterion. 
Size of the mass lesion less than 10cm recorded sonographically 
Absence of solid components  
Ascites should be absent 
Normal CA – 125 values 
Absence of family history of ovarian malignancy. 
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CHEMOTHERAPY(51) 
Very few patients with ovarian carcinoma are successfully treated 
with surgery alone. Rest of the patients require chemotherapy either 
before or after the surgery. 
INTRAPERITONEAL CHEMOTHERAPY(51) 
Instillation of chemotherapeutic agents  into peritoneal cavity . 
Advantages :  
No risk of systemic adverse effects 
Ability to attain high concentration at the local site 
Disadvantages : 
Inability to penetrate more than few millimeters from the site of 
instillation. 
Infection /  block of the subcutaneously placed tube for instillation 
of drugs. 
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NEOADJUVANT CHEMOTHERAPY 
Initially inoperable ovarian tumor 
Patient unfit for surgery 
 
Three or more cycles of chemotherapy 
 
Interval debulking surery 
 
Further rounds of chemotherapy 
MAINTANENCE  CHEMOTHERAPHY(52) 
50% of patients show recurrence even after complete resection of 
the tumor and chemotherapy. In order to prevent the recurrence , 
strategies were developed in maintanence therapy using niraparib. 
DRUGS USED IN CHEMOTHERAPY(51) 
Paclitaxel / Docetaxel  
Cisplatin / Carboplatin 
Doxorubicin 
Bevacizumab 
Olapraib / Rukaparib / Niraparib 
Pazopanib 
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AIMS AND OBJECTIVE 
 To assess and compare the accuracy of ultrasonography and MR 
imaging features in the detection and characterization of adnexal mass 
lesions with HPE as a gold standard 
To evaluate the ability of USG & MRI to determine which imaging 
features are predictive of malignancy. 
 INCLUSION CRITERIA: 
       Simple adnexal cyst  >5cm 
      Complex adnexal  lesions 
EXCLUSION CRITERIA: 
      Simple adnexal cyst  <5cm 
      Ectopic pregnancy 
      Ovarian torsion 
      MRI  contraindicated  patients – pace maker, joint implant prosthesis 
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MATERIALS AND METHODS 
At our institution female patients presenting  with lower abdominal 
pain and menstrual irregularities are evaluated in Department of 
Obstetrics and Gynaecology and then referred to Department of 
Radiodiagnosis for radiological evaluation. 
Forty five patients were referred for evaluation of  Ultrasonography 
and  contrast MRI . The patients were first subjected to ultrasound then 
dynamic MR  imaging  was done for those adnexal lesions greater than 5 
cm in size .The study was conducted after obtaining proper informed 
consent from the patient. As this was a prospective controlled study, 
ethical committee approval from Institutional Ethics Committee, Kilpauk  
Medical College, was obtained. 
All patients are subjected to  Transabdominal sonography using 
curvilinear probe in Aloka,Sonoscape,Esoate scanner 
In Ultrasonogram adnexal lesions were evaluated  for several 
features including content, nodularity , wall thickness , septal thickness , 
ascites and vascularity of the lesion 
 
 
50 
Then these patients are subjected to MRI and the following 
imaging features are evaluated. 
The Dynamic MR imaging features documented for evaluation 
include the  lesion size, content of lesion (solid only, mainly solid, solid–
cystic, mainly  cystic, and cystic only), wall thickness,  nodularity, septal 
thickness, early arterial phase enhancement, ascites, omental deposits and 
lymphadenopathy 
STUDY DESIGN 
All patients are subjected to Transabdominal sonography using 
curvilinear probe in Aloka, Sonoscape, Esoate scanner. Axial and sagittal  
Images of adnexal mass lesions are taken and then colour Doppler images 
also taken. 
The patients were subjected to magnetic resonance imaging using 
1.5 Tesla GE. The patients were examined in supine position and 
following sequences were taken: 
T1 axial 
T2 sagittal, coronal 
STIR coronal 
T1 contrast axial and coronal 
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Tesla (GE) machine was used. The following sequences were used: 
1. T2 W Axial 
TR: 7120  ms,  
TE:  90 ms,  
Flip angle 90* 
 Slice thickness 5mm,  
Matrix 256 x 256 
2. T1 W Axial 
TR: 740  ms,  
TE:  13 ms,  
Flip angle 90* 
Slice thickness 5mm,  
Matrix 256 x 256 
           3. STIR: 
TR: 6000  ms,  
TE:  70ms,  
TI : 230 ms 
Slice thickness 4 mm,  
Matrix 256 x 256 
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4.Contrast enhanced T1 images: 
Contrast-enhanced images were obtained after IV injection of 10 
ml  gadolinium.  
The dynamic contrast-enhanced fat-suppressed  T1-weighted MR 
imaging was performed through the lesion in the optimal plane  
This sequence was performed before and immediately after a rapid 
hand 
IV injection of 10ml of gadolinium  and then repeated at 30, 60, 
90, and 120 sec. 
TR: 900 
TE:15 
Flip angle: 90 degree 
Slice thickness: 4mm 
Matrix: 256x320 
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CASES 
Case 1: 38 years female patient presented with lower abdominal pain 
 
                        
 
 
USG shows well defined cystic lesion with multiple 
septations and nodularity – Malignant  
STIR images shows cystic lesion with septation 
and nodularity 
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T2W images 
hyperintense 
lesion with 
septation and 
nodularity 
Post contrast TI 
images shows  
septal and nodular 
enhancement - 
Malignant 
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HPE :  Mucinous cystadenocarcinoma 
 
 
 
 
 
 
 
56 
CASE 2 
32 years female patient presented with lower abdominal 
pain. 
 
 
 
 
USG shows well defined cystic lesion  in adnexa - Benign 
Well defined T1- Hypointense cystic  lesion in adnexa 
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Well defined T2- 
Hyperintense cystic  
lesion in adnexa - 
Benign 
HPE: Serous cyatadenoma 
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CASE 3 
21 years female patient presented with abdominal pain and 
menstrual irregularities. 
 
 
 
USG shows heteroechoic lesion in bilateral adnexa 
USG Doppler shows central vascularity - Malignant 
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T2 &STIR 
Heterointense lesion 
with cystic and solid 
component noted  in 
bilateral adnexa with 
omental deposits. 
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HPE :  Surface epithelial malignant tumor 
 
 
 
 
Post contrast TI  
sequence shows 
intense 
enhancement of 
the lesion 
Mailgnant 
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CASE 4 
45 years female patient presented with abdominal pain and 
menstrual irregularities. 
 
 
 
 
 
Well defined cystic lesion 
with septation in adnexa with 
peripheral vascularity - 
Benign 
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Well defined STIR Hyperintense cystic lesion with 
septation in adnexa 
Well defined T2 Hyperintense 
lesion with septation in adnexa 
- Benign 
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Variably-sized cysts and glands separated by fibrous septa. The 
septa vary in thickness and are lined by intestinal (more common) 
orendocervical epithelium. 
HPE : Mucinous cystadenoma 
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CASE  5 
 45 years female patient presented with abdominal pain. 
 
 
 
 
Cystic lesion with solid component noted in adnexa - Mailgnant 
T2 Heteriontense lesion with cystic & solid 
component in bilateral adnexa 
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STIR Heterointense lesion with cystic & solid component in bilateral 
adnexa with multiple omental deposits and ascites - Mailgnant. 
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High-grade tumor cells arranged in nests and clusters infiltrating 
the ovarian stroma. 
HPE: serous papillary cystadenocarcinoma 
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RESULTS AND STATISTICAL ANALYSIS 
The collected data were analysed with IBM.SPSS statistics 
software 23.0 Version. To describe about the data descriptive statistics 
frequency analysis, percentage analysis were used for categorical 
variables and the mean & S.D were used for continuous variables. 
Bar chart and pie chart also used for statistical analysis. 
The Receiver Operator Characteristic (ROC) curve analysis was 
used to find the Sensitivity ,Specificity ,PPV and NPV on comparison of 
USG and MRI with HPE.  
In the above statistical tool the probability value .05 is considered 
as significant level.  
DESCRIPTIVE STATISTICS 
Charecteristics N Minimum Maximum Mean 
Std. 
Deviation 
Age 45 16 76 37.64 12.617 
Thickness USG 26 2 4 2.992 0.5699 
RI USG 27 0.4 0.9 0.6844 0.16173 
Thickness MRI 26 2 4 3.304 0.5674 
Valid N 
(listwise) 
26 
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BILATERAL / UNILATERAL ADNEXAL MASS LESIONS 
 
Frequency Percent 
Bilateral 5 11.9 
Unilateral 40 88.1 
Total 45 100 
 
 
LATERALITY 
Bilateral Unilateral
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USG 
CONTENT – USG 
Nature of lesion Frequency Percent 
Cystic 38 84.4 
Solid-cystic 7 15.6 
Total 45 100 
 
NODULE – USG 
 
Frequency Percent 
Absent 40 88.9 
Present 5 11.1 
Total 45 100 
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ASCITES – USG 
 
Frequency Percent 
Absent 40 88.9 
Present 5 11.1 
Total 45 100 
 
 
VASCULARITY – USG 
 
Frequency Percent 
Absent 20 44.4 
Central vascularity 7 15.6 
Peripheral vascularity 13 28.9 
Septal vascularity 5 11.1 
Total 45 100 
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SEPTUM  CHARECTERISTICS – USG 
 
Frequency Percent 
Absent 19 42.2 
Present 26 57.8 
Total 45 100 
 
 
MRI 
 
CONTENT IN MRI 
Nature of lesion Frequency Percent 
Cystic 38 84.4 
Solid-cystic 7 15.6 
Total 45 100 
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NODULE – MRI 
 
Frequency Percent 
Absent 38 84.4 
Present 7 15.6 
Total 45 100 
 
 
SEPTUM  CHARECTERISTICS – MRI 
 
Frequency Percent 
Absent 19 42.2 
Present 26 57.8 
Total 45 100 
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ENHANCEMENT – MRI 
 
Frequency Percent 
Enhancement 11 26.7 
No enhancement 34 73.3 
Total 45 100 
 
 
ASCITES – MRI 
 
Frequency Percent 
Absent 40 88.9 
Present 5 11.1 
Total 45 100 
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OMENTAL DEPOSITS – MRI 
 
Frequency Percent 
Absent 41 91.1 
Present 4 8.9 
Total 45 100 
 
 
LYMPHADENOPATHY – MRI 
 
Frequency Percent 
Absent 42 93.3 
Present 3 6.7 
Total 45 100 
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USG vs MRI 
Septal thickness charecteristics 
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USG 
 
Frequency Percent 
+ ve 7 15.6 
- ve 38 84.4 
Total 45 100 
 
MRI 
 
Frequency Percent 
+ ve 11 24.4 
- ve 34 75.6 
Total 45 100 
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HPE 
 
Frequency Percent 
+ ve 12 26.7 
- ve 33 73.3 
Total 45 100 
 
USG * HPE Cross tabulation 
 
HPE 
Total 
+ ve - ve 
USG 
+ ve 7 0 7 
- ve 5 33 38 
Total 12 33 45 
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VARIABLES PERCENTAGE 
Sensitivity 58.3 
Specificity 100 
PPV 100 
NPV 86.8 
Over all Accuracy 79.15 
 
MRI * HPE Crosstabulation 
 
HPE 
Total 
+ ve - ve 
MRI 
+ ve 11 0 11 
- ve 1 33 34 
Total 12 33 45 
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VARIABLES PERCENTAGE 
Sensitivity 91.7 
Specificity 100 
PPV 100 
NPV 97.1 
Over all Accuracy 95.8 
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ROC Curve 
Case Processing Summary 
HPE Valid N (list wise) 
Positivea 12 
Negative 33 
 
Smaller values of the test result variable(s) indicate stronger 
evidence for a positive actual state. 
a. The positive actual state is + ve. 
AREA UNDER THE CURVE 
Test Result 
Variable(s) 
Area 
Std. 
Errora 
Asymptomatic 
Sig.b 
Asymptomatic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
USG .792 .092 .003 .611 .973 
MRI .958 .047 .000 .866 1.000 
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The test result variable(s): USG, MRI has at least one tie between 
the positive actual state group and the negative actual state group. 
Statistics may be biased. 
  a. Under the nonparametric assumption 
  b. Null hypothesis: true area = 0.5 
 
P- value is highly significant <0.01 
Age range 
  Frequency Percent 
Valid 
Percent 
Cumulative  
Percent 
Valid 
Upto 25 yrs 8 17.8 17.8 17.8 
26 - 35 yrs 11 24.4 24.4 42.2 
36 - 45 yrs 16 35.6 35.6 77.8 
46 - 55 yrs 8 17.8 17.8 95.6 
Above 55 
yrs 
2 4.4 4.4 100.0 
Total 45 100.0 100.0 
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Ovarian Tumors Frequency Percentag
e 
Benign serous cystadenoma 20 44.4 
Benign mucinous cystadenoma 13 28.9 
Surface epithelial carcinoma of ovary 2 4.4 
Malignant mucinous 
cystadenocarcinoma 
5 11.1 
Serous papillary cystadenocarcinoma 5 11.1 
 
Ovarian Tumors Findings 
Surface epithelial carcinoma of ovary 4.4 
Malignant mucinous cystadenocarcinoma 11.1 
Serous papillary cystadenocarcinoma 11.1 
Benign mucinous cystadenoma 28.9 
Benign serous cystadenoma 44.4 
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DISCUSSION 
The age group examined in our study  was from 16-76 
years..Among these the incidence of adnexal lesions were found to be 
more in the age group of 36-45 years and  followed by 26-35 years. 
Among these 45 patients, 5 had bilateral lesions and on HPE, all of 
these lesions were confirmed to be malignant. 
In Ultrasonogram adnexal lesions were evaluated  for several 
features including content, nodularity , wall thickness , septal thickness , 
ascites and vascularity of the lesion. 
In our study group solid cystic nature of the lesion was seen in 15.6% 
( 5 cases), Septal thickness > 3mm in  7 cases , nodularity was seen in 
11.6% (5 cases) and central / septal vascularity was seen in 
26.7%(12cases). 
Among these, all the cases having central and septal vascularity 
were found to be malignant. 
The Dynamic MR imaging features documented for evaluation 
include the  lesion size, content of lesion (solid only, mainly solid, solid–
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cystic, mainly  cystic, and cystic only), wall thickness , nodularity , septal 
thickness, early arterial phase enhancement, ascites , omental deposits 
and lymphadenopathy. 
Solid – cystic nature of the lesion was seen in 15.6% (5 cases) , 
septal thickness >3mm was seen in 11 cases, nodularity was seen in 
15.6% and early arterial phase enhancement was seen in 26.7% (11 case) 
are highly indicative of malignant ovarian tumors. 
The study included 45 patients with adnexal mass lesions. On 
Ultrasonogram there were 38 cases of benign ovarian lesions and 7 cases 
of malignant ovarian tumors. MR imaging studies of 45 patients showed  
33 cases to be of benign nature and 11 cases to be of malignant nature. 
Histopathological studies of postoperative specimens revelaed 33 cases to 
have benign tumor and 12 cases to have malignant features. 
Sohaib et al. (34) showed that from the analysis of the MR imaging 
features, “the most predictive characteristics of malignancy are 
vegetations/nodule  in a cystic lesion, presence of ascites, a maximal 
diameter greater than 6 cm, and necrosis in a solid lesion” ,in the same 
way our study also shows the presence of nodules in a cystic lesion, 
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presence of ascites and lesion size more than 6 cm suggestive of 
malignancy. 
Valentini et al.(28) suggested criteria for characterization of  
suspicious adnexal lesions.Features suggestive of malignancy as per the 
valentine et al study were “solid, solid/cystic enhancing masses (greater 
than 4 cm in maximum diameter) with papillary projections and irregular 
thick wall and septa greater than 3 mm) into a cystic lesion” as well as a 
“heterogeneous and early enhancement pattern”. Similar to  this study , 
the above features  in our study population  also had positivity for  
malignancy in HPE. 
Adumusili et al  (29) study  have  high specificity (94%) for 
establishing a benign diagnosis.  The specificity in our study  is 100%. 
Guerra et al study (27) on MRI had  a higher accuracy of 95% in 
differentiating between malignant and non-malignant adnexal lesions. 
The  diagnostic accuracy of our study is 95% similar to Guerra et al. 
Adumusili et al study (29) showed Sonographically indeterminate 
ovarian mass lesions evaluated with MRI had a  sensitivity and specificity 
of 100% and 94%, respectively. Result of our  study MRI had a 
sensitivity of 91.7% and specificity of 100% 
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Sohaib et al study (34) showed  overall diagnostic accuracy of 91% 
for distinguishing MR imaging features of benign from malignant 
adnexal lesions . the results of our  study show that the overall diagnostic 
accuracy of 95% for distinguishing benign from malignant adnexal 
lesions. 
Features that were shown not to be significantly different between  
benign and  malignant masses in our study  were wall thickness and size 
of the lesion. 
The one malignant lesion not detected in dynamic MR imaging 
was low grade mucinous cystadenocarcinoma. This lesion did not show 
septal enhancement in post contrast study.  Five malignant lesions not 
detected in ultrasonogram includes 4 cases of mucinous 
cystadenocarcinoma and 1 case of serous papillary cystadenocarcinoma. 
In all these 5 cases septal thickness was less than 3mm and nodularity 
was absent. 
In MRI characterization of adnexal mass lesions, enhancement of 
lesion , septal thickeness >3mm, nodularity of the lesion and ascites are 
highly suggestive of malignant nature of the lesion. 
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In Ultrasonographic characterization of adnexal mass lesions, 
septal thickness, nodularity, central and peripheral vascularity of the 
lesion are highly suggestive of malignancy 
The sensitivity, specificity, positive predictive value, negative 
predictive value, diagnostic accuracy of  Ultrasonogram in comparison 
with HPE were 58.3%, 100%, 100%, 86.8.5%, 79.15% respectively. 
In comparison with HPE , characterization of  the detected lesions 
as malignant, MR imaging had a  sensitivity of 91.7% , specificity of 
100% , positive predictive value  of 100% , a negative predictive value of 
97.1% , and an overall accuracy of 95.8% . 
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CONCLUSION 
Inspite of  development in advanced chemotherapy regimens and 
improved surgical approaches, ovarian carcinoma continues to be one of 
the leading cause of death from gynaecological malignancy.  
Treatment of adnexal mass lesion mandates stratification of risk 
based on imaging appearance of the mass. 
Ultrasonography is the initial imaging modality of choice for 
evaluation of adnexal mass lesions. But evaluation with MRI  is highly 
accurate for identifying the origin of a mass, characterizing its tissue 
content and staging & preoperative plan..  
Sensitivity and diagnostic accuracy for MRI is higher than USG. 
MRI is superior to Ultrasonogram in diagnosing and characterizing 
adnexal mass lesions. High accuracy of MRI contributes to preoperative 
planning of a sonographically indeterminate mass. 
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LIST OF ABBREVATIONS 
 
USG- Ultrasonography 
CT   - Computed Tomography   
MRI – Magnetic Resonance imaging 
STIR – short tau Inversion Recovery 
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PROFORMA 
 
 
Name  
Age  
Sex  
Address  
Phone no.  
Education  
Occupation  
General examination:                                      
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PATIENT CONSENT FORM 
 
STUDY DETAIL  :   
STUDY CENTRE :    
PATIENT’S NAME       :  
PATIENT’S AGE   :  
IDENTIFICATION NUMBER :   
I confirm that I have understood the purpose and procedure of the above study. 
I have the opportunity to ask questions and all my questions and doubts have 
been answered to my complete satisfaction.  
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected.  
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However I understand that my 
identity would not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including biochemical, radiological tests. 
                                                                                                                                                       
 
Signature/Thumb impression 
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PATIENT’S INFORMATION SHEET 
 
Magnetic resonance imaging (MRI) is a  medical imaging technique used 
in radiology to image the anatomy and the physiological processes of the 
body in both health and disease.MRI scanners use strong magnetic fields, 
radio waves, and field gradients to form images of our body. 
During the scan, you lie on a table that slides inside a tunnel-shaped 
machine. Doing the scan can take a long time from 30 minutes to 60 
minutes. The scan is painless. The MRI machine makes a lot of noise.  
The powerful magnetic field of the scanner can attract certain metallic 
objects known as ‘’ferromagnetic’’ objects, causing them to move 
suddenly and with great force towards the center of the MR system. 
Therefore, great care is taken to prevent Ferromagnetic objects from 
entering the MR system room. It is vital tom remove metallic objects in 
advance of an MRI exam, including watches, jewellery, and items of 
clothing that have metallic threads or fasteners. 
 A contrast agent called ‘’gadolinium’’ may be injected into a vein to help 
obtain a clearer picture of the area being examined. This is typically done 
through a small needle connected to an intravenous line that is placed in 
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arm or hand vein. MRI contrast agents do not contain iodine and 
therefore, rarely cause allergic reactions or other problems.   
Ultrasonography is a diagnostic medical procedure that uses sound waves 
to produce images on a screen, which allows medical providers to view 
internal structures of the body.    
You will be first subjected to ultrasonography  and  Dynamic contrast  
MR imaging  to characterise your  adnexal  pathology and  followed by  
postoperative correlation. 
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USG FEATURES 
S.No. 
Patient  
name 
Age 
Bilateral / 
Unilateral 
Content 
Wall 
characteristics 
Septum  
characteristics 
Ascites Doppler Lesion 
        Cystic Nodule Thickness   Vascularity RI   
1 Vijayalakshmi 50 unilateral cystic nil 3 _ nil 0.9 benign 
2 Govindammal 45 unilateral cystic nil 2.8 _ nil 0.8 benign 
3 Tamilselvi 40 unilateral 
Solid -  
Cystic 
present 4 present 
central 
vascularity 
0.55 malignant 
4 Kushpoo 24 unilateral cystic nil absent _ nil   benign 
5 Shanthi 53 unilateral cystic  nil 2 _ 
peripheral 
vascularity        
0.9 
0.9 benign 
6 Vishnupriya 21 bilateral  
solid-
cystic 
nil 3.5 _ 
central 
vascularity 
0.43 malignant 
7 Sunitha 32 unilateral cystic nil absent absent nil   benign 
8 Amudha 32 unilateral cystic nil absent nil nil   benign 
9 Kaliyammal 65 unilateral cystic nil 2.5 nil septal vascularity 0.6 benign 
10 Amudha 32 unilateral cystic nil absent nil 
peripheral 
vascularity 
0.8 benign 
11 Parvathy 45 bilateral  
solid-
cystic 
present 3.5 present 
central 
vascularity 
0.45 malignant 
12 Ranjitha 16 unilateral cystic nil absent absent nil   benign 
13 Stella mary 17 unilateral cystic nil 2.4 absent 
peripheral 
vascularity 
0.73 benign 
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14 Malarkodi 48 unilateral cystic nil absent nil nil   benign 
15 Devi 28 unilateral cystic nil 3 nil 
peripheral 
vascularity 
0.7 benign 
16 Valliammal 76 unilateral cystic nil 3 nil septal avscularity 0.65 benign 
17 Kokilavani 40 unilateral cystic nil absent nil nil   benign 
18 Ammu 28 unilateral cystic nil 3 nil 
peripheral 
vascularity 
0.73 benign 
19 Jayalakshmi 40 unilateral cystic nil absent nil nil   benign 
20 Kushpoo 24 unilateral cystic nil absent nil nil   benign 
21 Lakshmi 40 unilateral cystic nil 2.6   septal avscularity 0.6 benign 
22 Muniyammal 42 bilateral  
solid-
cystic 
present 3.5 present 
central 
avscularity 
0.45 malignant 
23 Manimegalai 28 unilateral cystic nil absent nil nil   benign 
24 Divya 26 unilateral cystic nil 3 nil 
peripheral 
vascularity 
0.6 benign 
25 Pushpa 18 unilateral cystic nil absent nil nil   benign 
26 Dhanalakshmi 38 bilateral  
solid-
cystic 
present 3.5 nil 
central 
vascularity 
0.54 malignant 
27 Velankanni 45 unilateral cystic nil absent nil nil   benign 
28 Thirupurasundari 50 unilateral cystic nil 2.9 _ 
peripheral 
vascularity 
0.8 benign 
29 Divya  21 unilateral cystic nil absent _ nil   benign 
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30 Revathy 37 unilateral cystic nil 3 nil septal vascularity 0.62 benign 
31 Poornima 20 unilateral cystic nil 3 nil 
peripheral 
vascularity 
0.75 benign 
32 Eshwari 35 unilateral cystic nil absent nil nil   benign 
33 Bhuvaneshwari 47 unilateral cystic nil 3 nil 
peripheral 
vascularity 
0.8 benign 
34 Sudhanderadevi 55 unilateral cystic nil absent nil nil   benign 
35 Muthulakshmi 45 unilateral cystic nil 3.2 nil 
peripheral 
vascularity 
0.9 benign 
36 Usha 28 unilateral cystic nil 2 nil 
peripheral 
vascularity 
0.9 benign 
37 Seeniyammal 40 bilateral  
solid-
cystic 
present 4 present 
central 
vascularity 
0.4 malignant 
38 Dhanalakshmi 32 unilateral cystic nil 2.5 nil 
periphaeral 
vascularity 
0.9 benign 
39 Arunavathi 40 unilateral cystic nil 2 nil 
peripheral 
vascularity 
0.85 benign 
40 Vijaya 50 unilateral cystic nil 2.9 nil septal vascularity 0.63 benign 
41 joyrita 38 unilateral cystic nil absent nil nil   benign 
42 malliga 50 unilateral Cystic nil absent nil absent   benign 
43 indhra 38 unilateral 
solid-
cystic 
present 4 nil 
central 
vascularity 
0.5 malignant 
44 amulu 35 unilateral cystic nil absent nil absent   benign 
45 sivagami 40 unilateral cystic nil absent nil absent   benign 
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MRI FEATURES 
S.No. 
Patient  
name 
Age 
Bilateral / 
Unilateral 
Content 
Wall 
charecteristics 
Septum 
characteristics 
Enhancement Ascites 
Omental  
deposits 
Lymph 
nodes 
Lesion 
 
        Nodule 
Thickness 
(mm) 
Present           
1 Vijayalakshmi 50 unilateral cystic nil 3mm nil no enhancement _ _ _ benign 
2 Govindammal 45 unilateral cystic  nil 3 nil no enhancement _ _ _ benign 
3 Tamilselvi 40 unilateral solid-cystic present 4 present enhancement present present present malinancy 
4 Kushpoo 24 unilateral cystic _   absent _ _ _ _ benign 
5 Shanthi 53 unilateral cystic   3   no enhancement _ _ _ benign 
6 Vishnupriya 21 bilateral  solid-cystic _ 3.5   intense enhancement _ present nil malignant 
7 Sunitha 32 unilateral cystic _   absent no enhancement _ _ _ benign 
8 Amudha 32 unilateral cystic nil   absent no enhancement _ _ _ benign 
9 Kaliyammal 65 unilateral cystic nil 2.8   septal enhancement _ _ _ malignant 
10 Amudha 32 unilateral cystic nil   absent no enhancement _ _ _ benign 
11 Parvathy 45 bilateral  solid-cystic present 3.8   solid part enhance present present present malignant 
12 Ranjitha 16 unilateral cystic nil   absent no enhancement _ _ _ benign 
13 Stella mary 17 unilateral cystic nil 2.7   no enhancement _ _ _ benign 
14 Malarkodi 48 unilateral cystic nil   absent no enhancement _ _ _ benign 
15 Devi 28 unilateral cystic nil 3   no enhancement _ _ _ benign 
16 Valliammal 76 unilateral cystic present 3.5   enhancement _ _ _ malignant 
17 Kokilavani 40 unilateral cystic nil   absent no  enhancement _ _ _ benign 
18 Ammu 28 unilateral cystic nil 3   no enhancement _ _ _ benign 
19 Jayalakshmi 40 unilateral cystic nil   absent no enhancemnt _ _ _ benign 
20 Kushpoo 24 unilateral cystic nil   absent no enhancement _ _ _ benign 
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21 Lakshmi 40 unilateral cystic absent 4   septal enhancement _ _ _ malignant 
22 Muniyammal 42 bilateral  solid-cystic present 3.5   enhancement present present present malignant 
23 Manimegalai 28 unilateral cystic absent   absent no enhancement _ _ _ benign 
24 Divya 26 unilateral cystic nil 2.8   no enhancement _ _ _ benign 
25 Pushpa 18 unilateral cystic nil   absent no enhancement _ _ _ benign 
26 Dhanalakshmi 38 bilateral  solid-cystic _ 4   Enhancement present _ _ malignant 
27 Velankanni 45 unilateral cystic nil   absent no enhancement _ _ _ benign 
28 Thirupurasundari 50 unilateral cystic nil 2.5   no enhancement _ _ _ benign 
29 Divya  21 unilateral cystic  nil   absent no enhancement _ _ _ benign 
30 Revathy 37 unilateral cystic present 4   septal enhancement _ _ _ malignant 
31 Poornima 20 unilateral cystic nil 3   no enhancement _ _ _ benign 
32 Eshwari 35 unilateral cystic nil   absent no enhancement _ _ _ benign 
33 Bhuvaneshwari 47 unilateral cystic nil 2.8   no enhancement _ _ _ benign 
34 Sudhanderadevi 55 unilateral cystic nil   absent no enhancement _ _ _ benign 
35 Muthulakshmi 45 unilateral cystic nil 3   no enhancement _ _ _ benign 
36 Usha 28 unilateral cystic nil 2   no enhancement _ _ _ benign 
37 Seeniyammal 40 bilateral  solid-cystic present 4   enhancement present _ _ malignant 
38 Dhanalakshmi 32 unilateral cystic nil 3   no enhancement _ _ _ benign 
39 Arunavathi 40 unilateral cystic nil 3 absent no enhancement _ _ _ benign 
40 Vijaya 50 unilateral cystic nil 3   septal enhancement _ _ _ malignant 
41 joyrita 38 unilateral cystic nil   absent no enhancement _ _ _ benign 
42 malliga 50 unilateral cystic nil   absent no enhancement _ _ _ benign 
43 indhra 38 unilateral solid-cystic present 4   Enhancement _ _ _ malignant 
44 amulu 35 unilateral cystic nil   absent no enhancement _ _ _ benign 
45 sivagami 40 unilateral cystic nil   absent no enhancement _ _ _ benign 
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HPE 
S.No. Patient name Age Findings 
1 Vijayalakshmi 50 Benign mucinous cystadenoma 
2 Govindammal 45 Benign mucinous cystadenoma 
3 Tamilselvi 40 Serous papillary  cystadenocarcinoma  
4 Kushpoo 24 Benign serous cystadenoma 
5 Shanthi 53 Benign mucinous cystadenoma 
6 Vishnupriya 21 Surface epithelial carcinoma ovary 
7 Sunitha 32 Benign serous cystadenoma 
8 Amudha 32 Benign serous cystadenoma 
9 Kaliyammal 65 Mucinous cystadenocarcinoma 
10 Amudha 32 Benign serous cysatdenoma  
11 Parvathy 45 Papillary serous cystadenocarcinoma 
12 Ranjitha 16 Benign serous cystadenoma 
13 Stella mary 17 Benign mucinous cystadenoma 
14 Malarkodi 48 Benign  serous cystadenoma  
15 Devi 28 Benign mucious cystadenoma 
16 Valliammal 76 Low grade mucious cyastadenocarcinoma 
17 Kokilavani 40 Benign serous cystadenoma 
18 Ammu 28 Benign mucinous cystadenoma 
19 Jayalakshmi 40 Benign serous cystadenoma 
20 Kushpoo 24 Benign serous cystadenoma 
21 Lakshmi 40 Low grade mucious cyastadenocarcinoma 
22 Muniyammal 42 Papillary serous cystadenocarcinoma 
23 Manimegalai 28 Simple serous cystadenoma 
24 Divya 26 Benign mucinous cystadenoma 
25 Pushpa 18 Benign serous cystadenoma 
26 Dhanalakshmi 38 Surface epithelial carcinoma ovary 
27 Velankanni 45 Benign serous cystadenoma 
28 Thirupurasundari 50 Benign mucinous cystdenoma 
29 Divya  21 Benign seous cystadenoma 
30 Revathy 37 Serous papillary cystadenocarcinoma  
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31 Poornima 20 Benign mucinous cystadenoma 
32 Eshwari 35 Benign serous cystadenoma 
33 Bhuvaneshwari 47 Benign mucinous cystadenoma 
34 Sudhanderadevi 55 Benign serous cystadenoma 
35 Muthulakshmi 45 Benign mucinous cystadenoma 
36 Usha 28 Benign mucinous cystadenoma 
37 Seeniyammal 40 Serous papillary cystadenocarcinoma 
38 Dhanalakshmi 32 Benign mucinous cystadenoma 
39 Arunavathi 40 Benign serous cystadenoma 
40 Vijaya 50 Mucinous cystadenocarcinoma 
41 Joyrita 38 Benign serous cystadenoma 
42 Malliga 50 Benign serous cyastadenoma 
43 Indhra 38 Mucinous cystadenocarcinoma 
44 Amulu 35 Benign serous cystadenoma 
45 Sivagami 40 Benign serous cystadenoma 
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